Citius Oncology (CTOR) Non-Current Assets (2022 - 2026)

Citius Oncology (CTOR) has reported Non-Current Assets for 5 consecutive years, with $69.4 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Non-Current Assets fell 5.47% year-over-year to $69.4 million in Q2 2026; TTM through Jun 2026 was $286.9 million, a 2.29% decrease from a year earlier, with the FY2025 full-year figure at $73.4 million, changed 0.0% from the prior year.
• Non-Current Assets was $69.4 million for Q2 2026 at Citius Oncology, down from $71.3 million in the prior quarter.
• Over five years, Non-Current Assets peaked at $73.4 million in Q3 2024 and troughed at $40.0 million in Q3 2023.
• A 5-year average of $66.4 million and a median of $71.3 million in 2026 frame the typical range for Non-Current Assets.
• The widest YoY moves for Non-Current Assets: up 83.5% in 2024, down 29.16% in 2024.
• Over 5 years, Non-Current Assets stood at $67.8 million in 2022, then gained by 7.01% to $72.6 million in 2023, then gained by 1.15% to $73.4 million in 2024, then retreated by 0.78% to $72.8 million in 2025, then dropped by 4.72% to $69.4 million in 2026.
• The last three Non-Current Assets figures came in at $69.4 million (Q2 2026), $71.3 million (Q1 2026), and $72.8 million (Q4 2025), per Business Quant data.